{
    "nct_id": "NCT04510311",
    "official_title": "An Exploratory Study of 3-[18F]Fluoro-para-hydroxyphenethylguanidine ([18F]3F-PHPG) in Patients With Neuroendocrine Tumors",
    "inclusion_criteria": "* Current neuroendocrine tumor diagnosis\n* Able to lie flat for 60 minutes\n* Provision of informed consent\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Pregnancy or lactation\n* Claustrophobia\n* Inability to lie flat for 60 minutes\n* Currently taking medications that may alter PET scans of neuroendocrine tumors with these tracers, including any of the following:\n\n  * Tricyclic antidepressants, which inhibit the norepinephrine transporter: desipramine, amitriptyline, imipramine\n  * Cold medications containing the sympathomimetic amines: phenylephrine, phenylpropanolamine, pseudoephedrine\n  * Nasal decongestants (some use phenylephrine as the active agent)\n  * Cocaine (which inhibits the norepinephrine transporter)\n  * Tetrabenazine (Xenazine), which inhibits the VMAT2 transporter\n  * Monoamine oxidase inhibitors (MAOI)\n  * Some antihypertensive drugs: reserpine, labetalol, Î±-methyldopa, clonidine",
    "miscellaneous_criteria": ""
}